MedTrace Logo

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

NCT01712815 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-08-14

No results posted yet for this study

Summary

This phase I trial studies the side effects of positron emission tomography (PET)/computed tomography (CT) in evaluating response to chemotherapy in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Conditions

  • HER2-positive Breast Cancer
  • Recurrent Breast Cancer
  • Stage IA Breast Cancer
  • Stage IB Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer

Interventions

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

questionnaire administration

Ancillary studies

RADIATION

fluorine F 18-clevudine

Undergo fluorine F 18-clevudine PET/CT scan

PROCEDURE

positron emission tomography/computed tomography

Undergo fluorine F18-clevudine PET/CT scan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Peter Conti, MD · University of Southern California

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-22
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712815 on ClinicalTrials.gov